Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda Qlex
pembrolizumab + berahyaluronidase alfa-pmph · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Subcutaneous treatment for adults and, where the corresponding intravenous solid tumor indication permits, children age 12 years or older with an eligible pembrolizumab indication, with the separately accelerated TMB-high use tracked on its own.
LAMPGEN ANALYSIS
Why it matters
The subcutaneous formulation extends approved solid tumor uses to an alternate route, supported by pharmacokinetic comparability.
What research teams should watch
Update route-specific order sets and scheduling; check each underlying indication and dosing schedule before use.
PRIMARY RECORDS